|
Q4 FY2025
As of Dec 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q4 FY2020
As of Dec 31, 2020
|
Q4 FY2019
As of Dec 31, 2019
|
|
|---|---|---|---|---|---|---|---|
| Assets | |||||||
| Current assets | |||||||
| Cash and cash equivalents | |||||||
| Restricted cash | |||||||
| Marketable securities | |||||||
| Accounts receivable | |||||||
| Biological assets | |||||||
| Inventory | |||||||
| Prepaid expenses and deposits | |||||||
| Investments | |||||||
| Assets held for sale | |||||||
| Net investment in subleases | |||||||
| Current assets | |||||||
| Non-current assets | |||||||
| Long-term deposits and receivables | |||||||
| Right of use assets | |||||||
| Property, plant and equipment | |||||||
| Net investment in subleases | |||||||
| Intangible assets | |||||||
| Investments | |||||||
| Equity-accounted investees | |||||||
| Goodwill | |||||||
| Total assets | |||||||
| Liabilities | |||||||
| Current liabilities | |||||||
| Accounts payable and accrued liabilities | |||||||
| Current lease liabilities | |||||||
| Derivative warrants | |||||||
| Current liabilities | |||||||
| Non-current liabilities | |||||||
| Lease liabilities | |||||||
| Other liabilities | |||||||
| Total liabilities | |||||||
| Shareholders’ equity | |||||||
| Share capital | |||||||
| Warrants | |||||||
| Contributed surplus | |||||||
| Contingent consideration | |||||||
| Accumulated deficit | |||||||
| Accumulated other comprehensive income | |||||||
| Total shareholders’ equity | |||||||
| Non-controlling interest | |||||||
| Total liabilities and shareholders’ equity | |||||||
Loading...